Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.

Amir Gougol¹, Paul Kwo¹, William Pike², Mehdi Farokhnia³, Gavin Hui², Saurabh Gombar², Babak Mirminachi⁴

¹Department of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA.

²Atropos Health Inc, Indianapolis, IN, USA.

³National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism, Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and, Bethesda, MD, USA.

⁴University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

PubMed DOI

Abstract

BACKGROUND: Metabolic dysfunction (MetD) and alcohol use disorder (AUD) frequently coexist as synergistic risk factors for steatotic liver disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established therapies for MetD, including type 2 diabetes mellitus (T2DM) and obesity. Recent studies suggested potential beneficial effects of GLP-1RA to decrease addictive behaviours in AUD. We…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Atropos Health
affiliation

MeSH Terms

Humans0Female0Male0Glucagon-Like Peptide-1 Receptor Agonists*Middle Aged0Retrospective Studies0Alcoholism*Alcohol Deterrents*Treatment Outcome0Tirzepatide0Diabetes Mellitus, Type 20Semaglutide0Metabolic Diseases*Adult0Acamprosate0United States0Aged0Obesity0Risk Factors0Naltrexone0

Keywords

GLP‐1RA; AUD; fatty liver diseasealcohol‐associated liver diseasemajor liver‐related outcomemetabolic dysfunction

Article Info

PMID: 41813606
DOI: 10.1111/apt.70596
Received: December 11, 2025
Accepted: February 16, 2026

How to Cite

Gougol A et al. Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications. Aliment Pharmacol Ther2026;63(11):1507-1516. doi:10.1111/apt.70596

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.